跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

SML0195

Sigma-Aldrich

米法莫肽

≥98% (HPLC)

同義詞:

CGP-19835, MTP-PE, MTP-脑磷脂, N-（N-乙酰胞壁酰）-L-丙氨酰-D-α-谷氨酰胺基-N- [(7R)-4-羟基-4-氧化-10-氧代-7- [（1-氧代十六烷基）氧]-3,5,9-三氧-4-磷酸五氯-1-基]-L-丙氨酸酰胺, 胞壁酰三肽磷脂酰乙醇胺

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C59H109N6O19P
CAS號碼:
83461-56-7
分子量：:
1237.50
分類程式碼代碼:
12352200
PubChem物質ID:
329825220
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

water: 2 mg/mL, clear (warmed)

起源

Novartis

儲存溫度

−20°C

SMILES 字串

CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC

InChI

1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79)/t43-,44-,45+,47+,48+,49-,50+,54+,55+/m0/s1

InChI 密鑰

ZVLWUMPAHCEZAW-KRNLDFAISA-N

應用

Mifamurtide 可用于免疫学和癌症相关细胞信号传导研究。

生化／生理作用

Mifamurtide 是一种免疫调节剂，可调节单核细胞和巨噬细胞的活化。Mifamurtide 上调促炎细胞因子如 TNF-α 的分泌、IL-1、IL-8、一氧化氮及前列腺素 E 2 和 D 2 。在儿童和青年高级别骨肉瘤中具有抗肿瘤作用。
Mifamurtide（胞壁酰三肽磷脂酰乙醇胺；MTP-脑磷脂；MTP-PE）是一种合成的亲脂性胞壁酰二肽类似物。它作为免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。
胞壁酰二肽的合成亲脂性类似物。免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。抗肿瘤免疫调节剂。

特點和優勢

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
0000044443
0000044415
014M4728V
113M4759V
111M4724V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Kanji Mori et al.
Expert review of anticancer therapy, 8(2), 151-159 (2008-02-19)
Osteosarcoma is the most common form of primary malignant bone tumor. The use of chemotherapy drugs with many side effects, including high-dose methotrexate, doxorubicin, cisplatin and ifosfamide, has greatly improved osteosarcoma survival compared with surgery alone. However, for 20 years
P Fedorocko et al.
Neoplasma, 50(3), 176-184 (2003-08-26)
The anti-tumor effects of i.p. administered cyclooxygenase inhibitor - diclofenac and i.v. administered liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) were investigated using a s.c. growing murine fibrosarcoma tumor. Tumor growth was assessed by measuring tumor volumes and survival of the mice.
Prescrire international, 20(115), 89-89 (2011-06-09)
The standard treatment for children and young adults with osteosarcoma consists of surgery, preceded and followed by methotrexate-based chemotherapy. Mifamurtide is an immunostimulant derived from a bacterial cell wall component. It is authorised in the European Union as an adjunct
James E Frampton
Paediatric drugs, 12(3), 141-153 (2010-05-21)
Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact) is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. In the EU, mifamurtide is indicated in children, adolescents, and young adults for the treatment of
L L Worth et al.
Hematology/oncology clinics of North America, 15(4), 723-740 (2001-10-26)
Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務